v3.26.1
Research, Consulting and Supply Agreements (Tables)
 6 Months Ended
Jun. 30, 2026
Research Consulting And Supply Agreements  
Schedule of Research and Development Expenses

The Company’s research and development expenses were comprised of the following:

 

(in thousands)            
   Three months ended   Six months ended 
(in thousands)  June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Clinical studies  $476   $734   $661   $1,328 
Manufacturing & Engineering   (93)   144    (23)   324 
Quality control   197    232    395    462 
Regulatory   9    64    38    140 
Totals  $589   $1,174   $1,071   $2,254 
Costs incurred pursuant to the Amarex agreements were as follows (thousands):

 

             
   Three months ended   Six months ended 
   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
                 
Pancreatic Cancer  $105   $94   $118   $192 
Post Covid Conditions   —    —    —    8 
Totals  $105   $94   $118   $200 
 Costs incurred pursuant to the Sterling Pharma agreements were as follows (thousands):

 

-            
  Three months ended   Six months ended 
  June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Total  $—   $—   $23   $— 
 Costs incurred pursuant to the Azenova agreements were as follows (thousands):

 

             
   Three months ended   Six months ended 
   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Total  $2   $—   $2   $15 
 Costs incurred pursuant to the Alcami agreements were as follows (thousands):  

 

             
   Three months ended   Six months ended 
   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Research and development expenses  $8   $3   $8   $10